Please login to the form below

Not currently logged in
Email:
Password:

FDA approves J&J's new HIV drug

The FDA approves Tibotec Therapeutic's new HIV drug Intelence for use with other HIV drugs in adults who have not been helped by other antiretroviral drugs

The FDA has approved Johnson & Johnson Ortho Biotech Products' subsidiary Tibotec Therapeutic's new HIV drug Intelence (etravirine).for use with other HIV drugs in adults who have not been helped by other antiretroviral drugs.

Intelence belongs to a class of HIV drugs called non-nucleoside reverse transcriptase inhibitors (NNRTIs) that block an enzyme that HIV needs to multiply.

Intelence was developed based on its ability to counter HIV strains that resist NNRTI therapy in two studies.

Together, the studies included 599 adult HIV patients. Half of the patients got Intelence in addition to their other HIV drugs. The other half of the group got a placebo pill along with their other HIV drugs.

After six months of treatment, more patients in the Intelence group had a drop in their blood level of HIV than patients in the placebo group. The long-term effects of Intelence aren't known, and the drug's safety and effectiveness haven't been studied in children younger than 16 or in pregnant women.

In August 2007, the FDA approved Pfizer's Selzentry. The drug inhibits one of two pathways that HIV uses to infect cells rather than treating the virus itself as the other HIV drugs are designed to do.

Intelence was approved as part of the FDA's accelerated-approval mechanism, which is aimed at getting life-saving treatments to market faster by allowing companies to submit less clinical data than usually required. Companies obtaining accelerated approval must keep studying drugs after they are on the market to gain full approval.

27th January 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anthill Agency

Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics